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Abstract
Background: Blood flow in the corpus luteum (CL) is associated with luteal function. The present
study was undertaken to investigate whether luteal function can be improved by increasing CL
blood flow in women with luteal phase defect (LFD).
Methods: Blood flow impedance in the CL was measured by transvaginal color-pulsed-Doppler-
ultrasonography and was expressed as a resistance index (RI). The patients with both LFD [serum
progesterone (P) concentrations < 10 ng/ml during mid-luteal phase] and high CL-RI (≥ 0.51) were
given vitamin-E (600 mg/day, n = 18), L-arginine (6 g/day, n = 14) as a potential nitric oxide donor,
melatonin (3 mg/day, n = 13) as an antioxidant, or HCG (2,000 IU/day, n = 10) during the
subsequent menstrual cycle.
Results: In the control group (n = 11), who received no medication to increase CL blood flow,
only one patient (9%) improved in CL-RI and 2 patients (18%) improved in serum P. Vitamin-E
improved CL-RI in 15 patients (83%) and improved serum P in 12 patients (67%). L-arginine
improved CL-RI in all the patients (100%) and improved serum P in 10 patients (71%). HCG
improved CL-RI in all the patients (100%) and improved serum P in 9 patients (90%). Melatonin had
no significant effect.
Conclusion: Vitamin-E or L-arginine treatment improved luteal function by decreasing CL blood
flow impedance. CL blood flow is a critical factor for luteal function.
Background
During corpus luteum formation, active angiogenesis
occurs after the ovulatory LH surge, and the corpus
luteum becomes one of the most highly vascularized
organs in the body [1-7]. Blood flow in the corpus luteum
is important for the development of the corpus luteum
and maintenance of luteal function [7-12]. Adequate
blood flow in the corpus luteum is necessary to provide
luteal cells with the large amounts of cholesterol that are
needed for progesterone synthesis and to deliver proges-
Published: 14 January 2009
Journal of Ovarian Research 2009, 2:1 doi:10.1186/1757-2215-2-1
Received: 8 December 2008
Accepted: 14 January 2009
This article is available from: http://www.ovarianresearch.com/content/2/1/1
© 2009 Takasaki et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Ovarian Research 2009, 2:1 http://www.ovarianresearch.com/content/2/1/1
Page 2 of 6
(page number not for citation purposes)
terone to the circulation. Color Doppler ultrasonography
is a useful and noninvasive technique for evaluating ovar-
ian vascular function, allowing visual observation of the
blood flow within the corpus luteum [13-16]. Blood flow
in the corpus luteum measured by color Doppler ultra-
sonography is well associated with luteal function [13-
21].
We recently reported changes in blood flow in the human
corpus luteum throughout the luteal phase and a close
relationship between luteal blood flow and luteal func-
tion [16]. Interestingly, luteal blood flow was significantly
correlated with serum progesterone concentrations during
the mid-luteal phase, and luteal blood flow was signifi-
cantly lower in women with luteal phase defect than in
women with normal luteal function, suggesting that low
blood flow of the corpus luteum is associated with luteal
phase defect. We, therefore, decided to study whether
luteal phase defect can be improved by increasing luteal
blood flow.
For this purpose, we focused on vitamin E and a potential
nitric oxide (NO) donor, L-arginine, to increase luteal
blood flow. Vitamin E has been shown to improve capil-
lary blood flow in a variety of organs not only by inhibit-
ing the breakdown of lipids in red blood cell membranes
[22,23] but also by protecting the endothelium from oxi-
dative stress [24,25]. NO release by vascular endothelial
cells via endothelial NO synthase (eNOS) leads to the
relaxation of vascular smooth muscle, mainly by activat-
ing cyclic guanosine monophosphate (cGMP) [26]. L-
arginine, a substrate of NO, increases hepatic and limb
blood flow [27,28]. In the present study, in order to exam-
ine the role of luteal blood flow in the regulation of luteal
function, we investigated whether luteal function can be
improved by increasing luteal blood flow in patients with
luteal phase defect.
It has also been reported that decreased blood flow causes
oxidative stress in a variety of organs [29-31]. Oxidative
stress is well known to inhibit luteal function [30,31]. In
fact, the decrease in ovarian blood flow inhibits luteal
function through oxidative stress in rats [29]. Therefore,
we further examined the possibility that the decrease in
blood flow of the corpus luteum inhibits luteal function
through oxidative stress in patients with luteal phase
defect.
Methods
The project was reviewed and approved by Institutional
Review Board of Yamaguchi University Graduate School
of Medicine. Informed consent was obtained from all the
patients in this study.
Patients
A total of 66 women who had both luteal phase defect and
high blood flow impedance of the corpus luteum [corpus
luteum-resistance index (CL-RI) ≥ 0.51] were recruited
into this study. When serum progesterone concentrations
were < 10 ng/ml during the mid-luteal phase, the patient
was diagnosed as having a luteal phase defect in this
study. CL-RI was measured during the mid-luteal phase,
and the cutoff value was determined as described below.
The mean age was 32.4 ± 4.3 years (mean ± SD), with a
range of 24–41 years. The patients were non-smokers and
free from major medical illness including hypertension;
they were excluded if they had myoma, adenomyosis,
congenital uterine anomaly, or ovarian tumors or if they
used estrogens, progesterone, androgens, or had chronic
use of any medication, including nonsteroidal anti-
inflammatory agents or anticonvulsants.
Ultrasonography
Blood flow in the corpus luteum was measured as
reported previously [16] using a computerized ultra-
sonography with an integrated pulsed Doppler vaginal
scanner [Aloka ProSound SSD-3500SV and Aloka UST-
984-5 (5.0 MHz) vaginal transducer, Aloka Co. Ltd,
Tokyo, Japan]. The high pass filter was set at 100 Hz, and
the pulse repetition frequency was 2–12 kHz, for all Dop-
pler spectral analyses. After the endovaginal probe was
gently inserted into the vagina, adnexal regions were thor-
oughly scanned. The ovary was identified, and color sig-
nals were used to detect the area with the highest blood
flow within the corpus luteum. Blood flow was identified
in the peripheral area of the corpus luteum [16]. The
pulsed Doppler gate was then placed on that area to
obtain flow velocity waveforms. An acceptable angle was
less than 60°, and the signal was updated until at least
four consecutive flow velocity waveforms of good quality
were obtained. Blood flow impedance was estimated by
calculating the resistance index (RI), which is defined as
the difference between maximal systolic blood flow (S)
and minimal diastolic flow (D) divided by the peak systo-
lic flow (S-D/S). Blood flow impedances were examined
in the corpus luteum during the mid-luteal phase (6–8
days after ovulation). The day of ovulation was deter-
mined by urinary LH, transvaginal ultrasonography and
basal body temperature records. Since the interobserver
coefficient of variation for Doppler flow measurements in
the present study was less than 10%, which is consistent
with the reports by Ziegler et al. [32] and Miwa et al. [33],
the Doppler flow measurements were judged to be repro-
ducible.
There was a significant negative correlation between CL-RI
and serum progesterone concentrations during the mid-
luteal phase from the data obtained from 36 women with
normal luteal function and 10 women with luteal phaseJournal of Ovarian Research 2009, 2:1 http://www.ovarianresearch.com/content/2/1/1
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defect (Fig. 1a). Receiver operating characteristic curve
(ROC) analysis was performed to determine the cutoff
value of the CL-RI providing the best value of the sensitiv-
ity and the specificity for determination of normal luteal
function and luteal phase defect. A cutoff value of 0.51
provided the best combination with 84.3% sensitivity and
85.6% specificity to discriminate between normal luteal
function and luteal phase defect (Fig. 1b).
Clinical studies
In order to investigate whether vitamin E or L-arginine
treatment has a potential to increase luteal blood flow and
to improve luteal function in patients with luteal phase
defect, the patients who showed both luteal phase defect
and high CL-RI (≥ 0.51) during the mid-luteal phase (6–8
days after ovulation) were given vitamin E (600 mg/day,
3 times per day orally; Eisai Co., Ltd., Tokyo, Japan; n =
18), or L-arginine (6 g/day, 4 times per day orally; Now
Foods, IL, USA; n = 14) during the luteal phase of the sub-
sequent menstrual cycle.
Decreased ovarian blood flow is reported to inhibit luteal
function via oxidative stress [29]. Therefore, to examine a
possibility that the decrease in luteal blood flow inhibits
luteal function through oxidative stress in women with
luteal phase defect, melatonin (3 mg at 22:00 hr orally;
KAL, Park City, UT, USA; n = 13) was given as an antioxi-
dant during the luteal phase of the subsequent menstrual
cycle. We confirmed that administration of 3 mg of mela-
tonin works as an antioxidant and suppresses oxidative
stress in the human ovulatory follicle [34].
Another 10 patients received luteal support with HCG
injection (2,000 IU/day, on days 3 and 5 after ovulation;
Gonatropin; Asuka Co., Ltd., Tokyo, Japan).
As controls, 11 patients with both luteal phase defect and
high CL-RI (≥ 0.51) during the mid-luteal phase received
no medication during the subsequent menstrual cycle.
To evaluate the effect of those treatments, serum proges-
terone concentrations and CL-RI were measured during
the mid-luteal phase (6–8 days after ovulation). Ultra-
sonogrphy was performed before blood sampling for
serum progesterone measurement.
Progesterone assay
Venous blood was taken for the determination of serum
progesterone concentrations on the day of the Doppler
examination during the mid-luteal phase. Progesterone
concentrations were measured by enzyme immunoassay
(ST AIA-PACK PROG, Tosoh Co., Ltd., Japan) as reported
Correlation between blood flow impedance of the corpus luteum and serum progesterone concentrations Figure 1
Correlation between blood flow impedance of the corpus luteum and serum progesterone concentrations. (a): 
Correlation between corpus luteum-resistance index (CL-RI) and serum progesterone concentrations (n = 46). (b): Receiver 
operating characteristic (ROC) curve analysis. CL-RI and serum progesterone concentrations were measured during the mid-
luteal phase (6–8 days after ovulation). Serum progesterone concentrations were significantly and negatively correlated with 
CL-RI (p < 0.01, single regression analysis). ROC curve analysis was performed to determine the cutoff value of the CL-RI pro-
viding the best values of sensitivity and specificity for determination of normal luteal function and luteal phase defect. The cutoff 
value of 0.51 provided the best combination with 84.3% sensitivity and 85.6% specificity to discriminate between normal luteal 
function and luteal phase defect.Journal of Ovarian Research 2009, 2:1 http://www.ovarianresearch.com/content/2/1/1
Page 4 of 6
(page number not for citation purposes)
previously [16]. The minimal detectable concentration is
estimated to be 0.1 ng/ml. Intra-assay and inter-assay
coefficients of variation were 9.9% and 11.3%, respec-
tively.
Statistical analyses
Single regression analysis, Wilcoxon signed-ranks test,
and chi-squared test with Bonferroni correction were car-
ried out using the computer program SPSS for windows
13.0. A value of P < 0.05 was considered significant.
Results
Vitamin E treatment
Eighteen patients who had both luteal phase defect and
high CL-RI (≥ 0.51) during the mid-luteal phase were
given vitamin E during the luteal phase of the subsequent
menstrual cycle. Fifteen patients out of 18 (83%) showed
improved CL-RI of less than 0.51, and 12 patients (67%)
developed serum progesterone concentrations of more
than 10 ng/ml (Table 1). In the control group, only one
patient out of 11 (9%) showed normal CL-RI and 2
patients (18%) showed normal serum progesterone con-
centrations (Table 1), suggesting that vitamin E signifi-
cantly improved CL-RI and serum progesterone
concentrations compared with the control (Table 1). Of
the 12 patients whose serum progesterone concentrations
improved, 11 patients showed improved CL-RI of less
than 0.51. Vitamin E significantly decreased CL-RI and
increased serum progesterone concentrations between the
treatment cycle and the previous cycle (Table 1).
L-arginine treatment
L-arginine treatment improved CL-RI in all the patients
(100%), and 10 patients out of 14 (71%) developed
serum progesterone concentrations of more than 10 ng/
ml (Table 1). Compared with the control, L-arginine sig-
nificantly improved CL-RI and serum progesterone con-
centrations (Table 1). L-arginine also significantly
decreased CL-RI and increased serum progesterone con-
centrations between the treatment cycle and the previous
cycle (Table 1).
Melatonin treatment
Melatonin treatment improved CL-RI in 4 patients out of
13 (31%) and improved serum progesterone concentra-
tions in 5 patients (38%) (Table 1). These effects were not
significant compared with the control (Table 1). Mela-
tonin treatment caused a significant increase in serum
progesterone concentrations in the treatment cycle com-
pared with the previous cycle, but the serum progesterone
levels were less than 10 ng/ml (Table 1).
HCG treatment
HCG treatment improved CL-RI in all the patients
(100%), and 9 patients out of 10 (90%) developed serum
progesterone concentrations of more than 10 ng/ml
(Table 1). Compared with the control, HCG significantly
improved CL-RI and serum progesterone concentrations
(Table 1). HCG also significantly decreased CL-RI and
increased serum progesterone concentrations between the
treatment cycle and the previous cycle (Table 1).
Table 1: Effects of vitamin E, L-arginine, melatonin, or HCG on corpus luteum resistance index and serum progesterone 
concentrations in patients with luteal phase defect.
CL-RI Serum P (ng/ml)
n previous cycle treatment cycle No. of < 0.51 previous cycle Treatment cycle No. of ≥ 10 ng/ml
Control 11 0.544 (0.515–0.643) 0.552 (0.483–0.633) 1 (9%) 7.2 (4.5–9.7) 8.2 (6.1–16.7) 2 (18%)
Vitamin E 18 0.550 (0.514–0.632) 0.448a (0.376–0.681) 15 (83%)c 8.0 (5.8–9.2) 11.6a (6.4–21.6) 12 (67%)d
L-arginine 14 0.538 (0.513–0.676) 0.419a (0.348–0.483) 14 (100%)c 7.6 (2.4–9.4) 12.8a (6.5–22.8) 10 (71%)d
Melatonin 13 0.538 (0.515–0.676) 0.530 (0.431–0.691) 4 (31%) 7.7 (2.4–8.9) 9.5b (2.9–29.1) 5 (38%)
HCG 10 0.545 (0.518–0.931) 0.447a (0.406–0.506) 10 (100%)c 8.1 (5.9–9.2) 14.7a (8.8–18.4) 9 (90%)c
Sixty-six patients with both luteal phase defect and high corpus luteum-resistance index (CL-RI ≥ 0.51) were recruited in this study. Vitamin E (600 
mg/day, n = 18), L-arginine (6 g/day, n = 14), or melatonin (3 mg/day, n = 13) was given after ovulation throughout the luteal phase. Controls 
received no medication (n = 11). Ten patients received luteal support with HCG (2,000 IU/day, on days 3 and 5 after ovulation). Data were 
compared between the treatment cycle and the previous cycle in each treatment, and between the control group and each treatment group. One 
patient out of 11 (9%) spontaneously improved in CL-RI and 2 patients (18%) did in serum progesterone (P) in the control group. By vitamin E 
treatment, 15 patients out of 18 (83%) showed improved CL-RI, 12 patients (67%) developed a serum P of more than 10 ng/ml. L-arginine 
treatment improved CL-RI in all the patients (100%) and serum P in 10 patients out of 14 (71%). Melatonin treatment had no significant effect on 
CL-RI. HCG treatment improved CL-RI in all the patients (100%) and serum P in 9 patients out of 10 (90%). Values show median with ranges. a; p 
< 0.01 and b; p < 0.05 v.s. previous cycle (Wilcoxon test). c; p < 0.01 and d; p < 0.05 v.s. control (x2-test with Bonferroni correction).Journal of Ovarian Research 2009, 2:1 http://www.ovarianresearch.com/content/2/1/1
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Discussion
Luteal phase defect has been implicated as a cause of infer-
tility and spontaneous miscarriage. Previous reports
including our recent report suggest that luteal phase defect
is associated with high blood flow impedance of the cor-
pus luteum, because luteal blood flow impedance in
women with luteal phase defect during the mid-luteal
phase was significantly higher than it was in women with
normal luteal function [13,14,16,19,20], and CL-RI was
negatively correlated with serum progesterone concentra-
tions during the mid-luteal phase. The present study
showed that treatments with vitamin E or L-arginine sig-
nificantly improved CL-RI and luteal function in patients
with luteal phase defect and high CL-RI. Most of the
patients whose CL-RI was improved by vitamin E or L-
arginine showed improvement of luteal function. Further-
more, in our unpublished data, administration of proges-
terone as a luteal support for the patients with both luteal
phase defect and high CL-RI did not improve CL-RI dur-
ing the mid-luteal phase, suggesting that progesterone
does not influence luteal blood flow impedance. It is,
therefore, likely that vitamin E or L-arginine improves
luteal function by decreasing luteal blood flow imped-
ance. The present result that decreasing luteal blood flow
impedance improved luteal function strongly suggests
that high blood flow impedance of the corpus luteum is
involved in the pathophysiology of impaired luteal func-
tion in patients with luteal phase defect. In other words,
luteal blood flow is a critical factor for luteal function.
Although there are no well-established methods for
increasing luteal blood flow, the present results appear to
be consistent with previous reports by ourselves and oth-
ers that vitamin E, L-arginine, or sildenafil citrate (Viagra)
improved endometrial growth in patients with a thin
endometrium by increasing uterine artery blood flow
[33,35-37].
Decreased ovarian blood flow is reported to inhibit luteal
function via oxidative stress [29]. Oxidative stress is well
known to inhibit luteal function [30,31]. It is of interest to
note that vitamin E acts as an antioxidant. The present
result revealed that melatonin used as an antioxidant did
not improve luteal blood flow impedance or luteal func-
tion, suggesting that vitamin E works via decreasing luteal
blood flow impedance rather than by acting as an antioxi-
dant.
Interestingly, HCG improved luteal blood flow imped-
ance as well as L-arginine. Although it is unclear how
HCG increases luteal blood flow, it may work through
vasoactive substances because there is some evidence that
luteal phase defect is caused by the altered regulation of
luteal blood flow during the mid-luteal phase [16].
Vasoactive substances such as NO, endothelin, or angi-
otensin have been reported to be involved in luteal func-
tion [11,38-41]. HCG increases eNOS expression in the
ovary of the rat and sheep [42,43], and increases rat ovar-
ian blood flow via locally produced NO [44]. Further
studies are needed to elucidate the relationship between
luteal blood flow and vasoactive substances in the corpus
luteum.
Conclusion
The present study is, to our knowledge, the first report to
show a close relationship between luteal blood flow
impedance, luteal function, and treatments that improve
luteal blood flow. Treatments that improve luteal blood
flow seem to improve luteal function in patients with
both luteal phase defect and high luteal blood flow
impedance. In other words, luteal blood flow is a critical
factor for luteal function. However, the present study is a
pilot study with a small number of subjects. A prospective
randomized controlled trial with larger samples is needed
to demonstrate the efficacy of these treatments for luteal
phase defect.
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